The year in cardiology: heart failure 2014

The year 2014 has become a remarkable year for heart failure.  The most important news was related to the results of PARADIGM, where LCZ696, the first-in-class angiotensin-receptor neprilysin inhibitor, proved to be superior to enalapril in reducing mortality and morbidity in patients with heart failure and reduced ejection fraction (HFrEF). Read more. Topics: Heart Failure (HF)
Source: ESC News and Press - Category: Cardiology Source Type: news